1. Introduction
===============

Hepatocellular carcinoma (HCC) ranks as the second most common cause of cancer-associated death in men and the sixth most common cause in women worldwide.^\[[@R1]\]^ About 55% of all HCC cases occur in China,^\[[@R2]\]^ but the incidence of HCC is increasing globally, especially in the United States and Europe.^\[[@R3],[@R4]\]^ HCC is an aggressive malignant tumor with fast infiltration growth, poor differentiation, and early metastasis.^\[[@R5]\]^ Despite tremendous improvements in early diagnosis and therapeutic strategies, most patients with HCC still have unfavorable long-term outcomes.^\[[@R6],[@R7]\]^ Therefore, it is imperative to identify novel effective biomarkers for evaluating the prognosis of patients with HCC to guide individualized therapy.

Alkaline phosphatases (ALPs) belong to the metalloenzyme family, which can catalyze the hydrolysis of organic phosphate esters in an alkaline environment with low substrate specificity.^\[[@R8]\]^ There are 4 genes encoding ALP: a tissue-nonspecific ALP gene located on 1p36.12 that is expressed in osteoblasts, hepatocytes, the kidneys, and the early placenta, and the 3 other tissue-specific ALP genes located on 2q37 and mainly expressed in the intestine, placenta, and germ cells.^\[[@R9]\]^ Serum ALP level can be used to evaluate the burden and prognosis of bone diseases such as osteosarcoma and cancers with bone metastasis.^\[[@R10]\]^ Additionally, increased serum ALP levels always occur in liver disease and may reflect liver injury.^\[[@R11]\]^ A growing number of studies have suggested that higher pretreatment serum ALP level is associated with poorer survival of HCC patients, but other studies have found no relationship. This inconsistency may be due to limitations such as small sample sizes and individual study methodology. Therefore, we conducted a meta-analysis by combining relevant data from previous studies to assess systematically the correlation between pretreatment serum ALP levels and the survival of HCC patients.

1.1. Materials and methods
--------------------------

This meta-analysis was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement issued in 2009.^\[[@R12]\]^ This study adhered to the principles of the Declaration of Helsinki, and the study protocol was approved by the Ethics Committee of Gansu Provincial Hospital of Traditional Chinese Medicine.

1.2. Literature search strategy
-------------------------------

We performed a comprehensive literature search in PubMed, EMBASE, and Web of Science up to October for eligible articles that assessed the association between pretreatment serum ALP levels and HCC patient survival. The searching terms included ("HCC" or "hepatocellular carcinoma" or "liver cancer" or "liver primary cancer" or "liver primary tumor" or "liver carcinoma"), and ("alkaline phosphatase") and ("survival" or "prognosis" or "prognostic" or "outcome"). The search strategy was as following: ((((((((HCC\[Title\]) OR hepatocellular carcinoma\[Title\]) OR liver cancer\[Title\]) OR liver primary cancer\[Title\]) OR liver primary tumor\[Title\]) OR liver carcinoma\[Title\])) AND alkaline phosphatase\[Title/Abstract\]) AND ((((survival\[Title/Abstract\]) OR prognosis\[Title/Abstract\]) OR prognostic\[Title/Abstract\]) OR outcome\[Title/Abstract\]). Only articles published in English were considered for this meta-analysis.

1.3. Selection criteria
-----------------------

All potential articles were screened and selected by 2 independent authors. Studies satisfying the following criteria were included:

1.  pathologically confirmed HCC;

2.  reported the association of pretreatment serum ALP level with OS or DFS/RFS in HCC patients;

3.  published in English; and

4.  directly provided HRs with corresponding 95% CIs for prognosis or provided relevant information to estimate HRs with corresponding 95% CIs.

The exclusion criteria included:

1.  reviews, letters, case reports, meeting abstracts, and meta-analyses;

2.  papers focusing on other cancers;

3.  studies enrolling HCC patients who had received anti-cancer therapy before testing baseline ALP level;

4.  incomplete texts; and

5.  studies with overlapping populations.

1.4. Data collection and quality assessment
-------------------------------------------

Two investigators independently reviewed eligible articles and extracted data. The collected data included the name of the first author, publication year, patient origin, number of patients, age, disease stage, primary treatment type, cut-off value, and HRs with corresponding 95% CIs for overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS). OS was regarded as the major outcome, since most eligible studies reported OS. If HRs with corresponding 95% CIs calculated by univariate and multivariate analyses were both reported, the latter was chosen since it adjusted for the confounding factors with more accuracy. When HRs with corresponding 95% CIs were not reported directly, we calculated these values from Kaplan--Meier curves using Engauge Digitizer version 4.1 ([http://digitizer.sourceforge.net](http://digitizer.sourceforge.net/)), according to Tierney\'s method. The quality of eligible articles was evaluated by 2 investigators using the Newcastle-Ottawa Quality Assessment Scale (NOS). The scores of NOS range from 0 to 9 points. In this meta-analysis, we considered 6 or more points for high quality.

1.5. Statistical analysis
-------------------------

STATA version 12.0 (Stata Corporation, College Station, TX) was used to perform the meta-analysis. Synthesized HRs with 95% CIs were used to describe the association between pretreatment ALP level and survival in HCC patients. HR \> 1 and 95% CI not containing 1 suggested that high pretreatment ALP level was associated with worse survival in HCC. Cochran *Q* and Higgins *I*^2^ statistics were used to evaluate the heterogeneity across studies. We considered *P* \< .05 and *I*^2^ \> 50% to indicate significant heterogeneity. All studies included in our meta-analysis were observational in design, so it remains unlikely that these studies were conducted under the same exact conditions. Therefore, the random-effects model was used for the statistical analysis in this meta-analysis. Subgroup and meta-regression analyses were performed to explore the sources of heterogeneity for OS by cut-off values for elevated ALP, primary treatment, mean age, and survival analysis type. Begg funnel plots and Egger linear regression tests were used to assess publication bias^\[[@R13],[@R14]\]^; when the *P* value of Egger linear regression tests was below .05 or the Begg funnel plot was asymmetric, it meant significant publication bias existed. If publication bias was significant, the trim-and-fill method was used to estimate a corrected effect size after adjustment, which helped to determine whether the publication bias substantially affected the robustness of the pooled results.^\[[@R15]\]^

2. Results
==========

2.1. Literature search and main characteristics of eligible studies
-------------------------------------------------------------------

The initial search yielded 439 relevant records. Twenty-three articles encompassing 24 studies, involving 16,551 patients, were ultimately included in this meta-analysis.^\[[@R16]--[@R38]\]^ The flow chart of the literature search and selection process is shown in Figure [1](#F1){ref-type="fig"}. Of the 24 included studies, 10 enrolled patients from China,^\[[@R17],[@R19],[@R20],[@R25],[@R31],[@R32],[@R35]--[@R38]\]^ 4 from Japan,^\[[@R21],[@R24],[@R28],[@R30]\]^ 2 from the United States of America,^\[[@R18],[@R27]\]^ 2 from Spain,^\[[@R26]\]^ 2 from Korea,^\[[@R22],[@R23]\]^ and 1 each from Germany,^\[[@R29]\]^ Israel,^\[[@R34]\]^ and France.^\[[@R33]\]^ One additional study included patients from China, Romania, and the United States of America.^\[[@R16]\]^ The cut-off value for high ALP level varied from 72.85 to 360 IU/L, though three studies did not report a cut-off value. With respect to HRs assessing the association between ALP and OS, most studies reported HRs generated from multivariate analyses; only 3 studies provided HRs generated from univariate analyses.^\[[@R17],[@R18],[@R21]\]^ In total, 21 studies investigated the relationship between pretreatment serum ALP level and OS.^\[[@R17]--[@R21],[@R24]--[@R38]\]^ Six studies assessed the association between pretreatment serum ALP and DFS/RFS.^\[[@R16],[@R22],[@R23],[@R35]--[@R37]\]^ The main characteristics of eligible are summarized in Table [1](#T1){ref-type="table"}. NOS scores for the included studies ranged from 6 to 8 (Table [1](#T1){ref-type="table"}), indicating high quality across studies.

![Flow diagram of the literature selection process.](medi-99-e19438-g001){#F1}

###### 

The main characteristics of the included studies in this meta-analysis.
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2.2. Association between pretreatment serum ALP level and prognosis in HCC patients
-----------------------------------------------------------------------------------

In total, 21 eligible studies provided data about the association between ALP and OS in HCC patients.^\[[@R17]--[@R21],[@R24]--[@R38]\]^ The pooled result showed that HCC patients with high serum ALP level had a significantly shorter OS (HR = 1.15, 95% CI: 1.12--1.19) (Fig. [2](#F2){ref-type="fig"}). Six studies reported the association between serum ALP level and DFS/RFS.^\[[@R16],[@R22],[@R23],[@R35]--[@R37]\]^ Considering the similarity between DFS and RFS, we merged the 2 outcomes together for meta-analysis. As shown in Figure [3](#F3){ref-type="fig"}, higher pretreatment serum ALP level also significantly correlated with poorer DFS/RFS (HR = 1.78, 95% CI: 1.37--2.31).
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2.3. Subgroup and meta-regression analyses
------------------------------------------

Subgroup and meta-regression analyses were performed to explore the sources of heterogeneity OS by cut-off for high ALP level \[≤100, 150--200, ≥200 IU/L, or not reported (NR)\], primary treatment type \[supportive, transarterial chemoembolization (TACE), liver resection, mixed therapies, or others\], median age (≤60, \>60 years, or NR), and survival analysis type (univariate or multivariate analysis). The results showed that significant heterogeneity still existed in subgroups of cut-off for high ALP level (Fig. [4](#F4){ref-type="fig"}), primary treatment type (Fig. [5](#F5){ref-type="fig"}), median age (Fig. [6](#F6){ref-type="fig"}), and survival analysis type (Fig. [7](#F7){ref-type="fig"}). Furthermore, the meta-regression analyses showed that these factors did not explain the major heterogeneity in OS (Table [2](#T2){ref-type="table"}). Overall, these results suggested that these factors might not be the contributors to the heterogeneity of OS. Although we failed to identify the sources of heterogeneity, these results showed that high serum ALP was closely associated with poor OS regardless of cut-off value (Fig. [4](#F4){ref-type="fig"}), median age **(**Fig. [5](#F5){ref-type="fig"}), primary treatment type (Fig. [6](#F6){ref-type="fig"}) and survival analysis type (Fig. [7](#F7){ref-type="fig"}), confirming the robustness of the pooled HR for OS. Due to the limited number of eligible studies about RFS/DFS, we did not perform a subgroup analysis for this outcome.
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Meta-regression for exploring the source of heterogeneity of the pooled HR of OS.
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2.4. Publication bias assessment
--------------------------------

Egger and Begg tests were used to evaluate potential publication bias in studies of OS. The result showed that the Egger test *P* value was below .05 and the funnel plot was asymmetrical, suggesting that there was significant publication bias for OS (Fig. [8](#F8){ref-type="fig"}A). Next, we performed the trim-and-fill method to explore whether the publication bias influenced the stability and reliability of the pooled HR for OS. The trim-and-fill analysis showed that the corrected funnel plot was symmetrical (Fig. [8](#F8){ref-type="fig"}B) and the pooled HR was still above 1 with its CI not containing 1, indicating that our overall pooled HR for OS was robust and reliable. The Egger and Begg tests were not conducted for publication bias evaluation for RFS/DFS due to the limited number of eligible studies investigating these outcomes.

![Funnel plot of publication bias assessment for OS (A) and the adjusted funnel plots of publication bias assessment for OS (B). OS = overall survival.](medi-99-e19438-g010){#F8}

3. Discussion
=============

To date, the association between pretreatment serum ALP level and prognosis in HCC patients remains controversial. Therefore, this meta-analysis was conducted to assess comprehensively the correlation between pretreatment serum ALP level and prognosis in HCC patients. Our meta-analysis demonstrated that high pretreatment ALP level was significantly associated with poor OS (HR = 1.14, 95% CI: 1.10--1.18) and RFS (HR=1.78, 95% CI: 1.37--2.31). Furthermore, our subgroup analysis and publication bias assessment verified that our overall pooled results were robust and reliable.

Several mechanisms may account for the association between serum ALP level and prognosis in HCC patients. First, cancer cells were found to exhibit higher ALP activity in the nucleolus and show a dynamic change in localization during cell cycles, indicating that ALP may facilitate tumor formation by modifying cell cycle regulation and cell proliferation.^\[[@R35],[@R36],[@R39]\]^ Second, an increased ALP level has been observed in several non-malignant disorders associated with inflammation, such as hepatitis, choledocholithiasis, cholangitis, and pancreatitis.^\[[@R36]\]^ Inflammation, as a hallmark of cancer, may contribute to cancer initiation and progression.^\[[@R40]\]^ Hence, an increased serum ALP level may be linked to poor prognosis by reflecting more severe inflammation in HCC patients. Third, ALP is widely considered as a biomarker for tumor metastasis, especially bone metastasis^\[[@R41]\]^; it may be this underlying process that contributes to the bad outcome of HCC patients. Taken together, this body of evidence supports our findings in the current meta-analysis. Nevertheless, additional studies are needed to elucidate further the mechanisms underlying the association between serum ALP level and prognosis in HCC patients.

Several limitations of our meta-analysis are noted here. First, while significant heterogeneity existed in the current meta-analysis, we failed to identify the sources of heterogeneity through subgroup analyses. Furthermore, bias may have been introduced through the retrospective design of the included studies and through the exclusion of studies published in languages other than English. Additionally, as some studies did not directly report the HR for the association between ALP level and prognosis, we had to extrapolate the HR manually from survival curves and might have performed statistical errors in the process. The inconsistency in cut-off values for high ALP also was likely to cause statistical error, though our subgroup and meta-regression analyses indicated that this might not account for the significant heterogeneity found. As all included studies were observational in design, there may be numerous confounding factors contributing to the study heterogeneity and discounting the reliability of our statistical results. However, few factors were subjected to subgroup and meta-regression analyses due to limited data availability. Thus, it is possible that the influence of the inconsistency in ALP cut-off values may be masked by the other factors, or cannot be identified using the current statistical method, when the weight of its contribution to overall heterogeneity is relatively low. Additionally, the cut-off values for high ALP level among the included studies were not identical, which may limit the generalizability of our conclusions into clinical practice. Finally, because many study conditions were not consistent across our sample, and because we were unable to perform stratified analysis due to limited data, the generalizability of our results may be limited. Further homogeneous clinical studies are required to explore the association between serum ALP level and prognosis in HCC patients.

4. Conclusion
=============

High pretreatment serum ALP level is closely correlated with poor survival in HCC patients and can be a potential biomarker for prognosis. Additional well-designed studies should be performed to validate our findings further.
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